Neurocrine Biosciences, Inc. (NBIX)

132.25 +1.61 (+1.23%) USD  |  NASDAQ  |  Feb 27, 16:00
132.22 -0.03 (-0.02%) After-Hours: 20:00
More

Neurocrine Biosciences Research and Development Expense (TTM) : 1.016B for Dec. 31, 2025

Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for NBIX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Glaukos Corp. 150.61M
Edgewise Therapeutics, Inc. 149.30M
Nuvalent, Inc. 306.97M
Marker Therapeutics, Inc. 14.74M
CapsoVision, Inc. 17.11M